Author | Tony Berberabe


Anti-HER2 Agents Explored Further in Gastric, Colorectal, and NSCLC Settings

July 07, 2020


At the recent 2020 American Society of Clinical Oncology Virtual Scientific Program, key research evaluating the use of anti-HER2 agents were highlighted across multiple solid tumors, including gastric or gastroesophageal junction adenocarcinoma, colorectal cancer, and non–small cell lung cancer.

Updated Guidelines Focus on Advanced Prostate Cancer

June 29, 2020


"Men with advanced prostate cancer have exhausted local therapies and are now moving on to systemic options."

Global Pandemic Paves Way to Modernize Clinical Trials

June 20, 2020


“We’ve seen remote data monitoring and remote data capturing. We are in a situation to continue moving forward, even in the midst of the pandemic, and, in fact, accelerate our position."

PFS Improvement Demonstrated With a Multinational Pediatric Cancer Registry in High-Risk Patients

May 28, 2020


"This is the first time that such a large precision oncology platform [involving] pediatric patients was assessed for its clinical benefit."